Core Viewpoint - AIM ImmunoTech Inc. is advancing its Phase 2 clinical study of Ampligen in combination with AstraZeneca's Imfinzi for treating metastatic pancreatic cancer, with promising early results and a commitment to ongoing updates [1][2][4]. Group 1: Clinical Study Details - The DURIPANC study is an exploratory, open-label trial with 18 subjects enrolled, focusing on patients with stable disease post-FOLFIRINOX [2]. - The study is a collaboration between AIM, AstraZeneca, and Erasmus Medical Center, with interim progress reports planned for mid-year and year-end [2]. - The lead investigator reported continued promising results in Progression-Free Survival and Overall Survival from Phase 1, supporting the ongoing Phase 2 study [2]. Group 2: Safety and Quality of Life - There has been no significant toxicity reported, indicating a favorable safety profile for Ampligen in a post-chemotherapy setting [3]. - Subjects receiving Ampligen have consistently reported a "high quality of life" during treatment [3]. Group 3: Future Milestones - Key milestones include completing subject enrollment by July 2026, full dosing by August 2026, and evaluating primary and secondary endpoints by December 2026 and June 2027, respectively [5]. - The primary endpoint is the Clinical Benefit Rate at 6 months, while secondary endpoints include Progression-Free Survival, Overall Survival, and immunogenic efficacy [5]. Group 4: Corporate Strategy - AIM emphasizes the potential for Ampligen's approval in pancreatic cancer, viewing this research as a significant opportunity for stockholders [4]. - The company aims to advance Ampligen towards Phase 3 clinical trials, which are often associated with substantial financial opportunities in the biotech sector [4].

Core Viewpoint - Glunz & Jensen Holding A/S has approved its financial outlook for 2026, indicating stable revenue and profit expectations compared to 2025 [1][3]. Financial Outlook - The expected revenue for 2026 is approximately DKK 140 million, which remains unchanged from the outlook for 2025 [3]. - The expected EBITDA for 2026 is approximately DKK 18 million, an increase from the outlook for 2025 which was approximately DKK 17 million [3]. - The expected profit before tax for 2026 is approximately DKK 12 million, up from the outlook for 2025 which was approximately DKK 11 million [3]. Additional Information - The outlook for 2026 is not influenced by the selling process of Selandia Park A/S [3]. - The annual report for 2025 is scheduled to be announced on March 17, 2026 [3].

Core Viewpoint - Akari Therapeutics has appointed Dr. Olga Anczukow to its Scientific Advisory Board, enhancing its expertise in RNA biology and cancer research, which is crucial for the development of next-generation therapeutics [1][2][4] Company Overview - Akari Therapeutics is an oncology biotechnology company focused on developing antibody drug conjugates (ADCs) with a unique payload, PH1, that targets RNA splicing in cancer cells [9] - The lead candidate, AKTX-101, targets the Trop2 receptor on cancer cells and utilizes a proprietary linker to deliver the PH1 payload directly into tumors, minimizing off-target effects [9] - AKTX-101 has shown significant activity in preclinical studies, demonstrating prolonged survival compared to traditional ADCs and potential synergy with checkpoint inhibitors [9] Dr. Olga Anczukow's Background - Dr. Anczukow is a recognized leader in RNA biology and cancer research, currently serving as an Associate Professor at The Jackson Laboratory for Genomic Medicine and a Co-Program Leader at the NCI-designated Jackson Laboratory Cancer Center [4][6] - Her research focuses on alternative RNA splicing and its misregulation in cancer, contributing to tumor initiation, progression, and therapeutic resistance [4][6] - Dr. Anczukow's previous work includes significant contributions to understanding breast cancer genetics and the role of RNA splicing in cancer biology [5][6] Research and Development Focus - The company aims to leverage Dr. Anczukow's expertise to shape research strategy and evaluate emerging scientific opportunities, particularly in RNA-targeted treatments [2][4] - Akari's innovative ADC discovery platform allows for the generation and optimization of ADC candidates tailored to specific antigen targets [9] - The ongoing research at The Jackson Laboratory integrates various methodologies to investigate how cancer cells adapt their splicing programs to survive and evade therapy [6]

Core Insights - Capgemini has formed a strategic partnership with OpenAI to enhance enterprise AI transformation through the Frontier platform, focusing on addressing business, data, and integration challenges [1][4] - The partnership aims to leverage Capgemini's industry expertise and OpenAI's advanced AI capabilities to create integrated solutions that drive measurable business outcomes [2][5] Group 1: Partnership Details - Capgemini is a founding member of the OpenAI Frontier Alliance, which will help businesses deploy AI securely and reliably across their operations [1][4] - The collaboration will establish a dedicated OpenAI Enterprise Frontier delivery function, comprising AI experts to support clients in scaling AI operations [4] Group 2: Market Context - 2026 is identified as a pivotal year for AI, with over half of organizations committing to long-term investments, shifting focus from experimentation to value creation [3] - The primary barrier to scaling AI is now recognized as the readiness of data and operating models rather than the technology itself [3] Group 3: Strategic Implications - The partnership is seen as a critical moment for enterprises, as organizations must scale AI to maintain competitive advantage [5] - Capgemini and OpenAI will co-develop industry-specific solutions targeting sectors such as consumer products, financial services, life sciences, and energy [4]

Core Viewpoint - Globex Mining Enterprises Inc. is updating shareholders on exploration drilling by Cartier Resources Inc. on Globex's Nordeau Royalty claims, highlighting the discovery of a new gold zone called the East Nordeau Zone, which is part of an aggressive drilling program [1][2]. Group 1: Exploration and Drilling Results - Cartier Resources has reported significant high-grade gold mineralization in the East Nordeau Zone (ENZ), which consists of two parallel high-grade gold zones, EN1 and EN2, with a confirmed strike length of 400 meters and open to depth [2][4]. - The ENZ is located 800 meters south of the Contact Sector and the high-grade North Contact Zone, indicating potential for further gold discoveries in the Nordeau Sector [2][4]. - Notable drill results include: - CA25-565: 23.2 g/t Au over 1.0 meters in EN1 Zone - CA25-570: 11.9 g/t Au over 1.0 meters in EN1 Zone and 14.1 g/t Au over 1.0 meters in EN2 Zone - CA25-572: 7.3 g/t Au over 1.0 meters in EN1 Zone [5]. Group 2: Future Plans and Expectations - Cartier plans further drilling to refine the geological model and verify the continuity of mineralization, with exploration drilling aimed at testing several new high-priority regional targets along the Nordeau Sector and the Cadillac Fault Zone [4][9]. - The success of Cartier's drilling on Globex's royalty claims is viewed positively, with anticipation for additional results from the North Contact Zone and the East Nordeau Zone as the drilling program progresses [9].

Core Insights - Palisade Bio, Inc. presented new translational data for PALI-2108, a targeted oral PDE4 inhibitor prodrug, at the 21st Congress of the European Crohn's and Colitis Organization (ECCO) in Stockholm, demonstrating localized target engagement and early clinical response within seven days [1][2][10] Group 1: Clinical Findings - In a Phase 1b trial involving patients with moderate-to-severe ulcerative colitis (UC), PALI-2108 achieved a 100% clinical response rate, with 40% of patients reaching clinical remission as measured by the modified Mayo Score [5][9] - The treatment resulted in significant downregulation of inflammatory and fibrosis-associated gene expression programs, including suppression of TNF-α, JAK–STAT, NF-κB, MAPK, and TGF-β pathways [5][6] - Histologic improvements were observed alongside reductions in fecal calprotectin and high-sensitivity C-reactive protein (hsCRP) levels, indicating a decrease in inflammation [5][6] Group 2: Mechanism of Action - PALI-2108 is designed for localized delivery to the terminal ileum and colon, where it is bioactivated by bacterial enzymes, allowing for targeted PDE4 inhibition at sites of inflammation while minimizing systemic exposure [7][9] - The prodrug's pharmacological activity was confirmed through RNA sequencing and pathway analyses, which showed localized suppression of inflammatory signaling networks in colonic tissue, with peripheral immune profiles remaining largely unchanged [4][6] Group 3: Safety and Tolerability - The safety profile of PALI-2108 was encouraging, with no serious adverse events reported among the 89 subjects in the study, supporting its potential as a differentiated treatment option for inflammatory bowel diseases [1][9] - The localized pharmacology of PALI-2108 aims to improve tolerability by reducing common side effects associated with systemic PDE4 inhibitors, such as diarrhea, nausea, and headache [7][8] Group 4: Future Development - Palisade Bio is advancing PALI-2108 into a Phase 2 clinical study to evaluate clinical remission, response, and pharmacodynamic biomarkers over a 12-week period, with plans for an extension phase to assess maintenance of remission [10]

Core Insights - Bond, Inc. has established a phase 1 commercial agreement valued at approximately $250,000 with a major pharmaceutical company, marking a significant step in its revenue growth strategy [2][3] - The agreement covers 5,000 employees and has the potential to expand the contract value beyond $1 million over time, indicating strong growth prospects for Bond's services [3][4] Revenue Growth - The $250,000 agreement contributes to Bond's Annual Recurring Revenue (ARR) and reflects ongoing traction within large multinational enterprises [5] - Initial enterprise engagements are viewed as foundational relationships that can lead to broader adoption and scalable ARR growth within large organizations [5] Strategic Importance - Executing agreements with global leaders is central to Bond's expansion and revenue growth strategy, aiming to establish a standard for corporate security [6] - The company anticipates that initial coverage will expand to include more employees over time, positioning Bond as a potential global standard for preventative security [6] Versatility and Market Potential - Bond's AI-powered platform is designed to address diverse workforce protection challenges across various employee functions and geographies, enhancing its applicability [7] - The platform's effectiveness, scalability, and affordability contribute to a significant Total Addressable Market (TAM), potentially reaching anyone with a connected device [8] Industry Recognition - Bond has been recognized as a sole supplier of AI-Powered Preventative Personal Security, which streamlines its market entry and reduces competitive tender processes [8] - The company has supported over 1.4 million security service requests, demonstrating its operational effectiveness and growing trust among corporations and public entities [11]

Core Viewpoint - Global Water Resources, Inc. has been invited to the 38th Annual ROTH Conference, highlighting its significance in the water resource management sector and its engagement with investors [1][2]. Company Overview - Global Water Resources, Inc. is a leading water resource management company that operates 39 systems providing water, wastewater, and recycled water services, primarily in metropolitan growth corridors around Phoenix and Tucson, Arizona [6]. - The company recycles over 1 billion gallons of water annually, totaling 19.3 billion gallons since 2004, showcasing its commitment to sustainable water management [6]. Conference Participation - The ROTH Conference will feature various formats including on-demand presentations, one-on-one meetings, and industry panels, attracting over 5,000 participants from institutional investors and equity analysts [2]. - CFO and SVP Mike Liebman will engage in one-on-one meetings with analysts and investors on March 23-24, discussing the company's market leadership and ongoing expansion efforts [2][3]. Strategic Focus - The company emphasizes its market leadership in utility consolidation, automation, and water resource management, which are critical for driving revenue growth [3]. - Global Water's Total Water Management (TWM) approach integrates the management of the entire water cycle, enhancing the beneficial use of recycled water and promoting conservation in water-scarce areas [7]. Industry Recognition - Global Water has received multiple awards, including national recognition as a 'Utility of the Future Today' for its superior water reuse practices, reflecting its leadership in the industry [8].

Core Viewpoint - Lakeland Industries, Inc. has appointed Lee D. Rudow to its Board of Directors, effective April 9, 2026, to enhance operational and M&A strategies as the company aims to expand its global footprint in the fire and industrial markets [1][4]. Group 1: Appointment and Experience - Lee D. Rudow brings over 33 years of experience in various leadership roles across startups, private equity-funded, and large industrial companies, currently serving as CEO of Transcat, Inc. for over 14 years [2][3]. - Rudow has a proven track record with 67 consecutive quarters of year-over-year service revenue growth at Transcat, highlighting his capability in driving growth and executing transformative acquisitions [2]. Group 2: Strategic Importance - The appointment of Rudow is seen as timely, providing Lakeland with insights into operational execution and strategic M&A integration, which are crucial for scaling its Fire and Industrial platforms globally [4]. - Rudow expressed his commitment to expanding Lakeland's portfolio and capabilities, aiming to position the company for long-term success in the protective clothing market [4]. Group 3: Company Overview - Lakeland Fire + Safety manufactures a comprehensive line of protective clothing and accessories for various industries, including healthcare and first responders, and offers decontamination, repair, and rental services [5]. - The company sells its products globally, reaching over 50 countries, with significant markets including China, the European Economic Community, Canada, and various regions in Latin America and Asia [5].

CAMBRIDGE, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage biotechnology company focused on unlocking the broad potential of RNA medicines to transform human health, today announced that Paul Bolno, MD, MBA, President and Chief Executive Officer, is scheduled to participate in an analyst-led fireside chat at the virtual Oppenheimer 36th Annual Healthcare Life Sciences Conference on Thursday, February 26, 2026 at 2:40 p.m. ET. A live webcast of the presentatio ...